News about Global Pharma

Magnet Biomedicine and Lilly to Develop Novel Molecular Glue Medicines

The collaboration will leverage Magnet's TrueGlue™ discovery platform to identify molecular glues capable of inducing protein proximity and cooperativity, enabling novel mechanisms of action to address difficult-to-drug targets spanning multiple diseases with unmet medical need.

Global Pharma | 01/03/2025 | By Aishwarya |  748

Foresight Diagnostics Expands Strategic Partnership with Allogene Therapeutics

Under the strategic collaboration, Allogene and Foresight will work together to support the development of Foresight Diagnostics' MRD assay in the EU, UK, Canada and Australia in support of Allogene's clinical development of cema-cel.

Global Pharma | 01/03/2025 | By Manvi |  276

Nxera Pharma and Holling to Commercialize Daridorexant in Taiwan

Daridorexant is an oral dual orexin receptor antagonist (DORA) for the treatment of insomnia that selectively binds to receptors of the wake-promoting neuropeptide orexin (OX1R and OX2R), inhibiting excessive wakefulness and facilitating the transition to sleep.

Global Pharma | 01/03/2025 | By Aishwarya |  523

ProRx Pharma Expands Production to Meet Demand for Drugs on FDA Shortage List

ProRx is currently expanding its operations to a total of 6,888 square feet, doubling its existing 3,400-square-foot pharmaceutical and manufacturing facility.

Global Pharma | 01/03/2025 | By Aishwarya |  603

USFDA Approves Fapon Biopharma's Investigational New Drug (IND) Application for FP008

Fapon Biopharma announced that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for FP008, its first-in-class immunocytokine designed to address the unmet need in patients with solid tumors refractory to anti-PD-1 therapy.

Global Pharma | 28/02/2025 | By Manvi |  370

Senores Pharmaceuticals Commence Operations at Greenfield API Facility at Mehsana, Gujarat

Senores Pharmaceuticals Ltd. has inaugurated and commenced manufacturing activities at its greenfield API manufacturing facility in Mehsana. This is Senores’ second API manufacturing facility and has an installed capacity of ~100 Metric Tons per Annum.

Global Pharma | 28/02/2025 | By Manvi |  636

Systech Develops UniSecure artAI for Life Sciences and Pharmaceutical Industries

artAI uses advanced machine vision and machine learning to create a digital blueprint of key packaging artwork features, enabling precise verification and quality inspection through pattern recognition.

Global Pharma | 28/02/2025 | By Aishwarya |  516

Zydus Lifesciences to Launch Protection Against New Strain of Influenza Virus

The Quadrivalent Inactivated Influenza vaccine has been developed at the Vaccine Technology Centre (VTC) in Ahmedabad which has proven capabilities in researching, developing, and manufacturing of safe and efficacious vaccines.

Global Pharma | 28/02/2025 | By Aishwarya |  452

Nxera Pharma Assigns Japan Rights to Cenerimod for Autoimmune Diseases to Viatris

Nxera will receive an upfront payment of USD 10 million from Viatris and is eligible to receive a milestone payment upon regulatory approval of cenerimod in Japan plus royalties on net sales should it be commercialized in the assigned territories.

Global Pharma | 28/02/2025 | By Aishwarya |  614

Venus Remedies Bags Exclusive Licensing Rights for MET-X from Infex Therapeutics

This strategic collaboration grants Venus Remedies the rights to spearhead clinical development, regulatory approvals, and commercialization of MET-X in India, focusing on its integration with meropenem to tackle infections resistant to conventional treatments.

Global Pharma | 28/02/2025 | By Aishwarya |  628